Pfizer, Merck KGaA's Bavencio flops in 'high-risk' stomach cancer trial

28th November 2017 Uncategorised 0

Pfizer and Merck KGaA are working to carve out a niche for immuno-oncology drug Bavencio in a crowded field. But a failed phase 3 trial in advanced stomach cancer just dinged their ambitions.

More: Pfizer, Merck KGaA's Bavencio flops in 'high-risk' stomach cancer trial
Source: fierce